• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 451533 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1416770876 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1416770876 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Shares of Bristol-Myers Squibb Rise to a New 52-Week High

Published on Fri, 03/01/2013 - 15:10
By Peter Chu

Bristol-Myers Squibb (NYSE:BMY) traded today at a new 52-week high of $37.25. So far today approximately 5.9 million shares have been exchanged, as compared to an average 30-day volume of 9.5 million shares.

In the past 52 weeks, Bristol-Myers Squibb share prices have been bracketed by a low of $30.64 and a high of $37.25 and are now at $37.08, 21% above that low price. Over the last five market days, the 200-day moving average (MA) has gone up 0.2% while the 50-day MA has advanced 0.9%.

Bristol-Myers Squibb (NYSE:BMY) is currently priced 3.2% above its average consensus analyst price target of $35.91. The stock should find initial support at its 50-day moving average (MA) of $34.99 and further support at its 200-day MA of $33.86.

Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures and sells pharmaceutical and nutritional products. The Company's products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

Post Earnings Update: International Pape...

When International Paper (NYSE:IP) reported earnings two weeks ago on November 4th, 201 ...

Protective Life Earnings Review: 19 Days...

Two weeks ago on November 3rd, 2014 Protective Life (NYSE:PL) reported earnings and ana ...

Earnings Look Back: Estee Lauder Is Up 1...

18 days ago, on November 4th, 2014, Estee Lauder (NYSE:EL) reported its earnings. Anal ...

Delek US Holdings Earnings Review: 17 Da...

When Delek US Holdings (NYSE:DK) reported earnings two weeks ago on November 5th, 2014, ...

Earnings Look Back: Stifel Financial Is ...

When Stifel Financial (NYSE:SF) reported earnings two weeks ago on November 6th, 2014, ...

Post Earnings Update: Dean Foods Has Cli...

A week ago on November 10th, 2014 Dean Foods (NYSE:DF) reported earnings and analysts, ...

Earnings Look Back: CF Industries Is Up ...

When CF Industries (NYSE:CF) reported earnings two weeks ago on November 5th, 2014, ana ...

Spectra Energy Earnings Hindsight: Up 0....

When Spectra Energy (NYSE:SE) reported earnings 17 days ago on November 5th, 2014, anal ...